Evidence map›Paper›PMID 28781887›Full record

ArticleNPJ genomic medicine2016

Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance.

Nicholas T Woods, Rebekah Baskin, Volha Golubeva, Ankita Jhuraney, Giuliana De-Gregoriis, Tereza Vaclova, David E Goldgar, Fergus J Couch, Marcelo Alex Carvalho, Edwin S Iversen and 1 more

Abstract read
In one paragraph

Article in NPJ genomic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. International journal of oncology · 2025
    Review
  4. Article
  5. Genes · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  19. Assessing the pathogenicity ofFrontiers in oncology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicholas T WoodsEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Rebekah BaskinCancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Volha GolubevaCancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Ankita JhuraneyCancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Giuliana De-GregoriisInstituto Nacional de Câncer, Programa de Farmacologia, Rio de Janeiro Brazil.
Tereza VaclovaCancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
David E GoldgarHuntsman Cancer Institute and Department of Dermatology, University of Utah, Salt Lake City, Utah, USA.
Fergus J CouchDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Marcelo Alex CarvalhoInstituto Nacional de Câncer, Programa de Farmacologia, Rio de Janeiro Brazil.
Edwin S IversenDepartment of Statistical Science, Duke University, Durham, NC, USA.
Alvaro Na MonteiroCancer Epidemiology Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
BRCA2 missense mutations and breast cancerR01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2007 to 2011
$3.0M
BRCA1 and BRCA2 missense mutations and breast cancer riskU01CA116167 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2013 to 2017
$2.7M
Moffitt Postdoctoral Training Program in Molecular & Genetic EpidemiologyR25CA147832 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EGAN, KATHLEEN M. · 2010 to 2014
$2.0M
Impact of BRCA1-mTORC2 interaction on breast cancer response to DNA damage and chR21CA184996 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WOODS, NICHOLAS TAYLOR · 2014 to 2015
$371k
NCI NIH HHS P30 CA036727NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA116167NCI NIH HHS R21 CA184996NCI NIH HHS R25 CA147832NCI NIH HHS U01 CA116167
6 · The paper itself

Abstract

Variants of Uncertain Significance (VUS) are genetic variants whose association with a disease phenotype has not been established. They are a common finding in sequencing-based genetic tests and pose a significant clinical challenge. The objective of this study was to assess the use of functional data to classify variants according to pathogenicity. We conduct functional analysis of a large set of

Identifiers

PMID28781887
PMCPMC5539989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.